Exelixis is an oncology-focused biopharmaceutical company that develops and commercializes cancer medicines. The company positions cancer as its core mission and advances a portfolio spanning diverse biotherapeutics and small-molecule programs.
Multiple oncology trials present recent results, including cabozantinib-nivolumab activity in non-clear cell RCC, savolitinib efficacy in MET-amplified gastric cancer, and induction nivolumab feasibility in HPV-driven oropharyngeal cancer.
Recent developments in breast cancer treatment include new clinical trials for advanced disease, findings on CDK4/6 inhibitor sequencing, and discovery of genetic markers explaining drug resistance in HER2-positive breast cancer.
Three comprehensive reports examine the monoclonal antibody landscape, covering CD47-targeted immunotherapy pipelines, competitive analysis of 180+ companies developing mAb therapeutics, and recombinant antibody market forecasts through 2033.
Multiple pharmaceutical companies have initiated clinical trials for metastatic castration-resistant prostate cancer in February 2026, with over 180 companies developing 200+ pipeline therapies. Studies include combination therapies and novel drug candidates targeting advanced disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07773454 |
Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07750158 |
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease |
NOT_YET_RECRUITING | PHASE3 |
| NCT07714551 |
Zanzalintinib in Unresectable and Progressive MPGGs |
NOT_YET_RECRUITING | PHASE2 |
| NCT07623460 |
Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07620574 |
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study |
ENROLLING_BY_INVITATION | PHASE3 |
| NCT07511504 |
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07489495 |
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) |
RECRUITING | PHASE3 |
| NCT07484139 |
H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07428616 |
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma |
RECRUITING | PHASE2 |
| NCT07283731 |
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma |
RECRUITING | PHASE2 |
